The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a huge mover today! About 7.62M shares traded hands or 367.48% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 13.31% since April 4, 2016 and is downtrending. It has underperformed by 14.40% the S&P500.
The move comes after 8 months positive chart setup for the $27.38 billion company. It was reported on Nov, 4 by Barchart.com. We have $168.33 PT which if reached, will make NASDAQ:ALXN worth $9.31B more.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage
Out of 20 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 15 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 75% are positive. Alexion Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The rating was initiated by FBR Capital on Thursday, September 15 with “Underperform”. On Friday, September 23 the stock rating was initiated by Wedbush with “Neutral”. The company was initiated on Thursday, November 3 by Deutsche Bank. The company was maintained on Tuesday, September 20 by Citigroup. The rating was maintained by Jefferies on Friday, September 23 with “Hold”. The firm has “Equal-Weight” rating given on Thursday, February 4 by Barclays Capital. Credit Suisse initiated it with “Neutral” rating and $201 target price in Wednesday, January 20 report. Stifel Nicolaus maintained it with “Buy” rating and $245 target price in Friday, December 11 report. As per Friday, July 31, the company rating was maintained by Brean Capital. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, July 29.
According to Zacks Investment Research, “Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.”
Insitutional Activity: The institutional sentiment increased to 1.19 in 2016 Q2. Its up 0.42, from 0.77 in 2016Q1. The ratio improved, as 51 funds sold all Alexion Pharmaceuticals, Inc. shares owned while 155 reduced positions. 58 funds bought stakes while 188 increased positions. They now own 212.84 million shares or 4.67% less from 223.26 million shares in 2016Q1.
Cornerstone Cap Mngmt Ltd last reported 2.9% of its portfolio in the stock. Livforsakringsbolaget Skandia Omsesidigt last reported 0.1% of its portfolio in the stock. Washington National Bank & Trust reported 16 shares or 0% of all its holdings. Opus Point Prns Management Limited Company has invested 1.95% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Deere & Com holds 0.1% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 15,471 shares. Regions Finance holds 0.03% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 20,381 shares. Teachers Advsrs Inc has 753,833 shares for 0.15% of their US portfolio. Van Eck Associates Corp owns 174,634 shares or 0.1% of their US portfolio. Bp Public Ltd Com accumulated 0.03% or 7,000 shares. Rafferty Asset Management Limited Liability has 4,695 shares for 0.04% of their US portfolio. Gsa Prtnrs Llp owns 13,192 shares or 0.09% of their US portfolio. The Guernsey-based Airain has invested 0.99% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Gateway Inv Advisers Limited Liability accumulated 184,840 shares or 0.19% of the stock. Rhumbline Advisers last reported 353,921 shares in the company. Baker Bros Advsrs Lp owns 6.54 million shares or 8.01% of their US portfolio.
Insider Transactions: Since May 13, 2016, the stock had 0 insider purchases, and 19 sales for $4.73 million net activity. On Tuesday, September 6 the insider Thiel Carsten sold $125,940. MACKAY MARTIN also sold $570,284 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. 277 shares were sold by Sinha Vikas, worth $37,988. Shares for $45,530 were sold by Hallal David on Monday, August 8. O’Neill Julie also sold $82,089 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, September 2. Moriarty John B had sold 135 shares worth $18,514. The insider BELL LEONARD sold $138,511.
Another recent and important Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news was published by Barrons.com which published an article titled: “Alexion Pharma Fairly Valued Despite Strong Q3” on November 01, 2016.
ALXN Company Profile
Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Firm is focused on the development and commercialization of life-transforming therapeutic products. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.